Association between serum leucine-rich alpha-2-glycoprotein levels and characteristic enteroclysis findings in small intestinal Crohn’s disease
Authors:
Open Access
- 18 February 2026
- journal article
- Vol. 8 (1) , otag012
Abstract
Enteroclysis provides a whole picture of mucosal and wall-structural information that is advantageous in assessing small intestinal Crohn’s disease (CD). Leucine-rich alpha-2-glycoprotein (LRG) is an acute-phase protein that has been shown to be increased in active CD. We sought to explore the association of LRG with the presence of typical CD findings in enteroclysis. Patients with small intestinal CD whose serum LRG and C-reactive protein (CRP) were measured within 30 days before or after enteroclysis were selected, and were categorized by the presence of longitudinal ulcer, cobblestone appearance, and stricture/narrowing. Levels of LRG were compared by the type and the extent of lesions. Detection performances of LRG and CRP were compared for the presence of each type of lesion. Serum LRG levels were significantly higher in patients who had enteroclysis findings than patients with no findings (23.5 ± 9.2 vs. 12.8 ± 3.0 μg/dL, P < .00001). The level of LRG was not affected by disease extent or history of bowel resection. LRG over 16.3 μg/dL had good detection accuracy for the presence of CD lesions with an area under the receiver operating characteristic curve of 0.85 (95% confidence interval: 0.75-0.95). The association of LRG with the presence of CD-specific lesions was significantly higher than CRP, especially for the presence of stricture/narrowing (AUC: 0.82 vs. 0.67, P = .005) and longitudinal ulcer (AUC: 0.93 vs. 0.80, P = .017). Elevation of serum LRG is associated with the presence of typical CD lesions in the small intestine that may be found in entericlysis.Keywords
This publication has 29 references indexed in Scilit:
- Development of the Crohnʼs disease digestive damage score, the Lémann scoreInflammatory Bowel Diseases, 2011
- iTRAQ-based proteomic identification of leucine-rich α-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseasesAnnals of the Rheumatic Diseases, 2010
- The Natural History of Adult Crohn's Disease in Population-Based CohortsAmerican Journal of Gastroenterology, 2010
- Top-down therapy for IBD: rationale and requisite evidenceNature Reviews Gastroenterology & Hepatology, 2010
- Up-regulation of the expression of leucine-rich α2-glycoprotein in hepatocytes by the mediators of acute-phase responseBiochemical and Biophysical Research Communications, 2009
- Biological therapies in inflammatory bowel disease: top-down or bottom-up?Current Opinion in Gastroenterology, 2007
- The Montreal classification of inflammatory bowel disease: controversies, consensus, and implicationsGut, 2006
- Technical refinements in enteroclysisRadiologic Clinics of North America, 2003
- Isolierung und Charakterisierung eines bisher unbekannten leucinreichen 3.1S-α2-Glykoproteins aus HumanserumHoppe-Seyler´s Zeitschrift Für Physiologische Chemie, 1977
- Crohn's disease of the large intestineGut, 1964